CAMBRIDGE, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., today announced that it will report its financial results for the third quarter of 2006 on Friday, October 27, 2006 before the U.S. financial markets open.
The company will also be hosting an analyst luncheon on Friday, October 27, 2006 at 11:30 a.m. ET to discuss the financial results for the quarter, review data from Idenix’s hepatitis B and hepatitis C clinical programs, and to discuss the company’s pipeline. The presentations will begin at 11:45 a.m. ET and will be accessible via webcast and teleconference dial-in. To listen to a live audio webcast and view the accompanying slides of the event, go to “Calendar of Events” in the Idenix Investor Center at http://www.idenix.com or http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=131556&eventID=1403521 on the Internet, or dial (US) 800-706-7741/(Intl) 617-614-3471, Code 96733381. To ensure a timely connection, please log in ten minutes before the event is scheduled to begin. An archive of this webcast will also be available at 5:00 p.m. ET on October 27, 2006 on the Idenix website in the Investor Center under “Past Events” until 5:00 p.m. ET on November 10, 2006.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix’s current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus. For more information on Idenix, please visit http://www.idenix.com.
Idenix Pharmaceuticals’ Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
Idenix Pharmaceuticals, Inc.
CONTACT: Media Contact: Teri Dahlman +1-617-995-9905, or InvestorsContact: Amy Sullivan +1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com/
